Alogliptin

Alogliptin
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	21 h
Izlučivanje	Renalno (76%), fekalno (13%)
Identifikatori
CAS broj	850649-61-5
ATC kod	A10BH04 (WHO)
PubChem	CID 11450633
DrugBank	DB06203
ChemSpider	9625485
ChEBI	CHEBI:72323
ChEMBL	CHEMBL376359
Hemijski podaci
Formula	C18H21N5O2
Molarna masa	339,392
	SMILES CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O; ;
	InChI InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1 ; Key:ZSBOMTDTBDDKMP-OAHLLOKOSA-N ;

Alogliptin je organsko jedinjenje, koje sadrži 18 atoma ugljenika i ima molekulsku masu od 339,392 Da.^[1]^[2]^[3]^[4]^[5]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	5
Broj donora vodonika	1
Broj rotacionih veza	3
Particioni koeficijent^[6] (ALogP)	1,3
Rastvorljivost^[7] (logS, log(mol/L))	-2,4
Polarna površina^[8] (PSA, Å²)	93,7

Reference

^ Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A (2008 Mar). „Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects”. Clin Ther. 30 (3): 513—27. PMID 18405789. doi:10.1016/j.clinthera.2008.03.005. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A (2008 Mar). „Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A random ized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes”. Clin Ther. 30 (3): 499—512. PMID 18405788. doi:10.1016/j.clinthera.2008.03.004. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Golightly, L. K.; Drayna, C. C.; McDermott, M. T. (2012 Aug 1). „Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors”. Clin Pharmacokinet. 51 (8): 501—14. PMID 22686547. doi:10.2165/11632930-000000000-00000. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.